Its announcement will come within the heels of an analogous licensing arrangement supplied in February to Adastra Labs, which had until now focused on crafting cannabis extracts. Adastra's license also will allow it to make and market psilocybin and psilocin – hallucinogens extra normally called magic mushrooms that produce effects similar to LSD